With decades of expertise, ILC Dover continues to lead the #pharmaceuticalindustry with tried and true products like DoverPac®, designed in collaboration with Eli Lilly to provide high levels of reliable containment during charging and offloading operations. Explore this trusted product's full capabilities: https://lnkd.in/eB_esaeF #Pharma
ILC Dover’s Post
More Relevant Posts
-
The #pharma industry faces unique third-party risks that require TPRM automation to help them stay ahead of these challenges. Learn more in our latest white paper!
Pharma and life sciences organizations face a wealth of #thirdpartyrisks. They must demonstrate transparency across their organization and supply chains. In our latest white paper, we break down key areas of focus for the #pharma industry, and #TPRM best practices to help manage risks and evolving stakeholder expectations. https://lnkd.in/eyesi-Xq
To view or add a comment, sign in
-
Pharma and life sciences organizations face a wealth of #thirdpartyrisks. They must demonstrate transparency across their organization and supply chains. In our latest white paper, we break down key areas of focus for the #pharma industry, and #TPRM best practices to help manage risks and evolving stakeholder expectations. https://lnkd.in/eyesi-Xq
New White Paper: Third-Party Risk & Resilience in the Pharmaceutical Industry
aravo.com
To view or add a comment, sign in
-
So true! Pharma and life science require focused customized solutions
Pharma and life sciences organizations face a wealth of #thirdpartyrisks. They must demonstrate transparency across their organization and supply chains. In our latest white paper, we break down key areas of focus for the #pharma industry, and #TPRM best practices to help manage risks and evolving stakeholder expectations. https://lnkd.in/eyesi-Xq
New White Paper: Third-Party Risk & Resilience in the Pharmaceutical Industry
aravo.com
To view or add a comment, sign in
-
Five Pharma Priorities for 2024: Setting a Realistic Regulatory & Quality Roadmap As we move into 2024….the pharma industry remains volatile. So what constitutes a sensible roadmap, in light of the multiple priorities vying for attention? Here’s a quick roundup of the important considerations. Kate Coleman, Our VP of Quality and Compliance, Provides an overview in our latest blog posting. Read more here: https://lnkd.in/eDjTHPPV . #QualityCompliance #pharma #regulatoryaffairs
To view or add a comment, sign in
-
-
The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. Ricky Yuen and Nick Porter check in on how pharma and states are responding to the program as it changes. https://bit.ly/3KG2LmT #healthcare #pharma #drugpricing
To view or add a comment, sign in
-
Payers representing more than 50.5 million commercial lives already engage with specialty benefit managers for at least one therapeutic area. MMIT’s Stephen Callahan explains what this means for #pharma companies—and why the future might include pharma/SBM contracting. Click to read about it in Fierce Pharma: https://lnkd.in/gD85G-BU #SpecialtyBenefitManagers #SBMs #PharmaCompanies #MarketAccess
To view or add a comment, sign in
-
-
Pharmaceutical companies need real-time supply chain information from all third-party logistics partners to fuel better decision making. Here are the key takeaways from our recent webinar on how to get that information in a fast, simple, cost-effective way: https://bit.ly/3LLCBQo #pharma #supplychain
To view or add a comment, sign in
-
-
Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: While Eli Lilly and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now amongst the 10 most valuable companies in the world, across all industries. #Pharmaindustries #Top20 #Lilly #Pharmacy #Pakistan
To view or add a comment, sign in
-
-
Fierce Pharma's latest report unveils the anticipated pharmaceutical shifts of 2024. Delve into the impending generics and biosimilars competition facing industry leaders. From industry giants to niche players, discover the impending transformations shaping the healthcare landscape. #KrugAssociates #PatentExpirations #HealthcareTrends #PharmaInsights #HealthcareShifts
The top 10 drugs losing US exclusivity in 2024
fiercepharma.com
To view or add a comment, sign in
-
Another National Association of Chain Drug Stores (NACDS) in the books! Great seeing both current and future partners! With all the BluPax Pharma growth, Haley is now helping me with vendors! She and I both look forward for more growth to come💙 #nacdstse #distribution #pharma #supplychain
To view or add a comment, sign in
-